Q3 2019 Investor Presentation

Focus on operating excellence and fiscal discipline driving continued improvements in operating leverage ($ in millions) Non-GAAP Operating Profit Margin $750 $500 $250 $- ©2019 ResMed I Q3 2019 Investor Presentation | 39 26.9% 27.4% $665 $591 12% $159 3Q18 15% Non-GAAP Operating Income ■Non-GAAP Revenue $182 3Q19 ResMed

View entire presentation